Is Supriya Lifescience Ltd (SUPRIYA) a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Supriya Lifescience Ltd is a good quality company .

Is Supriya Lifescience Ltd (SUPRIYA) undervalued or overvalued?

The key valuation ratios of Supriya Lifescience Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone .

What is Supriya Lifescience Ltd (SUPRIYA) share price return in the past 10 years?

Data is not available for this company

Is Supriya Lifescience Ltd (SUPRIYA) a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Supriya Lifescience Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

What is the share price of Supriya Lifescience Ltd (SUPRIYA)?

Company share prices are keep on changing according to the market conditions. The current trading price of Supriya Lifescience Ltd (SUPRIYA) on 17-Apr-2026 16:59:59 at 16:59 is 649.75.

What is the market cap of Supriya Lifescience Ltd (SUPRIYA)?

Market capitalization is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 17-Apr-2026 at 16:59, the market cap of Supriya Lifescience stood at Rs. 5229.37 Cr.

What is the P/E ratio of Supriya Lifescience?

The latest standalone P/E ratio of Supriya Lifescience as of 17-Apr-2026 is 28.23.

What is the P/B ratio of Supriya Lifescience Ltd (SUPRIYA)?

The latest standalone P/B ratio of Supriya Lifescience Ltd (SUPRIYA) as of 17-Apr-2026 is 4.62.

What is the 52-week high and low of Supriya Lifescience Ltd (SUPRIYA)?

The 52-week high of Supriya Lifescience Ltd (SUPRIYA) is Rs. 831.00 and the 52-week low is Rs. 545.65.

What is the TTM revenue of Supriya Lifescience Ltd (SUPRIYA)?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Supriya Lifescience is Rs. 735.46 (Cr.).

Supriya Lifescience Ltd (SUPRIYA) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Supriya Lifescience Ltd (SUPRIYA)
Brand: Supriya Lifescience

10 Year X-Ray :

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	12.3%	11.5%	13.8%	36.5%	49.7%	60.1%	43.3%	18.7%	22.3%	27.6%	-
Value Creation Index ⓘ	-0.1	-0.2	0.0	1.7	2.7	3.5	2.1	0.3	0.6	1.0	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	171	184	213	278	312	391	530	461	570	696	735
Sales YoY Gr.	-	7.5%	16%	30.5%	12.2%	25.5%	35.5%	-13%	23.7%	22.1%	-
Adj EPS ⓘ	0.8	0.7	0.9	5.3	10.1	16.9	18.9	11.2	14.8	23.3	23
YoY Gr.	-	-19.1%	26.5%	520.9%	88.6%	67.7%	11.7%	-40.8%	32.5%	57.6%	-
BVPS (₹) ⓘ	4.8	5.5	7.5	12.8	20.4	36.7	76.5	86.9	101.3	123.8	140.6
Adj Net Profit ⓘ	6.2	5	6.3	39.1	73.7	124	152	89.9	119	188	185
Cash Flow from Ops. ⓘ	13.5	27.3	27.8	48.9	116	75.9	48.8	63.6	113	165	-
Debt/CF from Ops. ⓘ	9.6	5.1	4.7	1.8	0.7	0.9	0.4	0.3	0	0	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	16.9%	17.5%	9.5%	22.1%
Adj EPS ⓘ	44.7%	18.3%	7.4%	57.6%
BVPSⓘ	43.6%	43.5%	17.4%	22.2%
Share Price	-	-	42.4%	-12.9%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	15.6	11.3	12.5	52.6	60.7	59.2	34.3	13.7	15.7	20.7	17.4
Op. Profit Mgn % ⓘ	11.9	9.3	10.3	23.8	31.7	44.3	40.4	27.9	30.8	37.5	35.9
Net Profit Mgn % ⓘ	3.6	2.7	3	14.1	23.7	31.6	28.6	19.5	20.9	27	25.2
Debt to Equity ⓘ	3.7	3.5	2.4	1	0.6	0.3	0	0	0	0	-
Working Cap Days ⓘ	217	220	174	141	166	158	140	206	179	163	110
Cash Conv. Cycle ⓘ	70	65	54	26	22	19	51	82	53	47	91

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 17.40%

Sales growth has been subdued in last 3 years 9.53%

Net Profit has been subdued in last 3 years 7.35%

Sales growth is not so good in last 4 quarters at 9.55%

	Standalone	Consolidated
TTM EPS (₹)	23	-
TTM Sales (₹ Cr.)	735	-
BVPS (₹) ⓘ	140.6	-
Reserves (₹ Cr.) ⓘ	1,115	-
P/BV ⓘ	4.62	-
PE ⓘ	28.23	-

From the Market
52 Week Low / High (₹)	545.65 / 831.00
All Time Low / High (₹)	170.05 / 841.70
Market Cap (₹ Cr.)	5,229
Equity (₹ Cr.)	16.1
Face Value (₹)	2
Industry PE ⓘ	42.1

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	171	184	213	278	312	391	530	461	570	696
Operating Expenses ⓘ +	151	166	191	213	213	218	316	332	395	436
Manufacturing Costs	12	16	21	27	24	23	34	50	57	75
Material Costs	107	123	136	147	138	128	196	181	222	211
Employee Cost	10	13	16	19	26	33	49	56	68	81
Other Costs ⓘ	21	15	18	21	25	34	37	46	49	69
Operating Profit ⓘ	20	17	22	64	98	173	214	128	176	261
Operating Profit Margin (%)	11.5%	9.3%	10.3%	23.2%	31.6%	44.3%	40.4%	27.9%	30.8%	37.5%
Other Income ⓘ +	2	7	9	8	11	5	8	10	11	10
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Interest ⓘ	10	12	11	10	7	4	4	3	5	2
Depreciation ⓘ	4	5	5	5	6	7	10	12	16	20
Profit Before Tax ⓘ	8	8	14	57	96	167	207	123	166	248
Tax ⓘ	2	2	6	18	23	44	55	34	47	61
Profit After Tax	6	6	9	39	73	124	152	90	119	188
PAT Margin (%)	3.3%	3.1%	4.1%	14.2%	23.6%	31.6%	28.6%	19.5%	20.9%	27.0%
Adjusted EPS (₹)	0.8	0.8	1.2	5.4	10.0	16.9	18.9	11.2	14.8	23.4
Dividend Payout Ratio (%)	26%	0%	0%	0%	20%	3%	3%	5%	5%	4%

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	41	46	55	94	149	269	616	699	815	997
Share Capital ⓘ	15	15	15	15	15	15	16	16	16	16
Reserves ⓘ	26	31	40	79	135	254	600	683	799	981
Debt +	129	140	121	85	79	67	21	17	0	0
Long Term Debt	34	45	35	8	2	0	0	0	0	0
Short Term Debt	95	95	86	77	77	67	21	17	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	50	41	42	44	49	51	49	64	60	75
Others Liabilities ⓘ	12	15	28	30	59	58	49	40	49	46
Total Liabilities ⓘ	231	241	245	253	336	445	735	820	924	1,117
Fixed Assets
Net Fixed Assets ⓘ +	75	89	91	85	98	100	190	262	310	453
Gross Block	89	98	96	95	114	123	223	306	371	534
Accumulated Depreciation	14	9	5	10	16	23	33	45	61	81
CWIP ⓘ	25	36	34	35	40	79	43	68	149	148
Investments ⓘ	0	0	0	0	0	0	0	25	64	63
Inventories	53	38	32	31	49	72	92	116	85	118
Trade Receivables	42	50	53	60	52	74	115	85	112	134
Cash Equivalents	7	6	3	2	2	89	228	158	75	79
Others Assets ⓘ	28	23	32	41	95	31	66	108	129	121
Total Assets ⓘ	231	241	245	253	336	445	735	820	924	1,117

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	14	27	28	49	116	76	49	64	113	165
PBT ⓘ	8	8	14	57	96	167	207	123	166	248
Adjustment ⓘ	13	16	16	13	10	5	7	5	2	14
Changes in Working Capital ⓘ	-7	3	1	-7	37	-67	-104	-34	-17	-38
Tax Paid ⓘ	-0	-0	-3	-14	-27	-30	-61	-31	-38	-59
Cash Flow From Investing Activity ⓘ +	-33	-27	-5	5	-25	-47	-60	-124	-174	-152
Capex	-18	-10	-5	5	-25	-47	-60	-108	-146	-162
Net Investments	0	0	0	0	0	0	0	-25	-39	1
Others ⓘ	-15	-17	0	0	0	0	-0	9	11	10
Cash Flow From Financing Activity ⓘ +	21	-2	-20	-50	-29	-15	150	-10	-22	-8
Net Proceeds from Shares ⓘ	1	-1	0	0	0	0	200	0	0	0
Net Proceeds from Borrowing ⓘ	15	0	-9	-27	-6	-2	0	0	0	0
Interest Paid ⓘ	-10	-13	-11	-10	-6	-4	-4	-0	-1	-2
Dividend Paid ⓘ	0	0	0	0	-18	-4	-4	-5	-5	-6
Others ⓘ	16	12	-1	-13	0	-4	-42	-5	-17	-0
Net Cash Flow ⓘ	2	-2	3	4	62	15	139	-70	-83	4

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	17.2	15.05	18.38	53.11	60.42	59.17	34.34	13.66	15.73	20.74
ROCE (%)	12.27	11.48	13.8	36.52	49.67	60.12	43.34	18.71	22.31	27.63
Asset Turnover Ratio	0.92	0.83	0.98	1.29	1.22	1.1	1	0.66	0.74	0.77
PAT to CFO Conversion(x)	2.33	4.5	3.11	1.26	1.59	0.61	0.32	0.71	0.95	0.88
Working Capital Days
Receivable Days	76	86	78	64	57	53	59	71	55	57
Inventory Days	90	85	53	35	41	52	51	74	57	48
Payable Days	135	134	111	107	123	143	93	114	102	116

About Supriya Lifescience Ltd

The company was incorporated as ‘Supriya Lifescience Limited’ pursuant to a certificate of incorporation dated March 26, 2008 issued by the Registrar of Companies, Maharashtra at Mumbai (RoC), upon the conversion of ‘M/s Supriya Chemicals’, a partnership firm, into a public limited company, in accordance with the provisions of Part IX of the Companies Act, 1956. The company commenced operations pursuant to a certificate for commencement of business dated April 1, 2008 issued by RoC.

The company is a global leading manufacturer of Active pharmaceutical Ingredients. The company’s pharmaceutical business is organized into domestic and export sales, according to the geographies in which it operates. It has grown its API business in several countries across Europe, Latin America, Asia (excluding India), North America and India. The company’s customers include global pharma companies such as Syntec Do Brasil LTDA, American International Chemical Inc and AT Planejamento E Desenbolvimento De Negocios Ltda, with whom it has business relationship for over nine years, and Suan Farma Inc, Acme Generics LLP, Akum Drugs Ltd and Mankind Pharma Ltd with whom it has business relationship for over four years. Its products are registered with various international regulatory authorities such as USFDA, EDQM, NMPA (previously known as SFDA), KFDA, PMDA, TGA and Taiwan FDA.

Business area of the company

The company is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients (APIs), with a focus on research and development. The company has niche product offerings of various APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and antiallergic.

Awards, accreditations or recognitions

2009: Certificate of Excellence for outstanding Export Performance in the product group Chemicals, Drugs, Pharma and Allied Products (MSME) awarded by Federation of Indian Export Organisations.
2010: Special Recognition National Award for Research and Development awarded by Ministry of Micro Small and Medium Enterprises, Government of India.
2016: Export House for the Year for 2015-16 awarded by Directorate of Industries, Government of Maharashtra.
2016: Export Achievement for 2015-16 in the product group Basic Chemical, Pharmaceutical & Cosmetics Products (MSME) awarded by Directorate of Industries, Government of Maharashtra.
2017: Export House for the Year for 2016-17 awarded by Directorate of Industries, Government of Maharashtra
2017: Export Achievement for 2016-17 in the product group Basic Chemical & Pharmaceutical Cosmetics (SSI) awarded by Directorate of Industries, Government of Maharashtra.
2019: Outstanding Export Performance Award for the year 2018-19 for product group API / Bulk Drugs by Pharmaceuticals Export Promotion Council of India.

Major events and milestones

2008 Incorporation of the Company upon its conversion from a partnership firm to a public limited company.
2009: Started production of Ketamine Hydrochloride.
2010: CEP (Certificate of Sustainability) granted for Chlorphenamine Maleate.
2011: IDL granted for Chlorphenamine Maleate.
2013: COFEPRIS and KFDA approval granted.
2014: USFDA approval granted
2014: IDL granted for Brompheniramine Maleate.
2015: EUGMP and EDQM approval granted.
2017: CEP (Certificate of Sustainability) granted for Pheniramine Maleate.
2017: Second time USFDA approval granted.
2018: CEP (Certificate of Sustainability) granted for Brompheniramine Maleate, Mepyramine Maleate & Ketamine Hydrochloride.
2020: Third time USFDA approval.
2021: CEP (Certificate of Suitability) granted for Pentoxifylline, Esketamine Hydrochloride and Salbutamol Sulphate.
2021: NMPA approval granted.
2021: Health Canada approval.

Build a Stress-Tested Portfolio.

Our Sapphire Advisory uses the ABC Concept to ensure you never have to panic during a market correction.

Core Stocks

STABILITY

Booster Stocks

GROWTH

Amplifier Stocks

ASYMMETRY

● Conflict-Free ● SEBI Registered ● 15Y+ Track Record

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Supriya Lifescience Ltd (SUPRIYA) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Supriya Lifescience Share Price